FBR Capital Starts Achillion Pharmaceuticals (ACHN) at Outperform, $16 PT
September 14, 2016 5:31 PM
FBR Capital initiates coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform rating and a price target of $16.00.Analyst Christopher ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
